KOSDAQOthers0007J0

Inventera

₩9,780▼ 9.28%2026-10-02 close

Market Cap

₩76.8B

Turnover

₩2.4B

Volume

240,000 shares

Shares out.

7.9M

PER

—

PBR

—

EPS

—

Dividend Yield

—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-10-02 close

Report overview

INV-002 Phase 3 Done: Regulatory Clearance Is the Deciding Factor

Inventera is advancing toward commercialization of its proprietary iron-based nano-MRI contrast agent, with the completion of INV-002's domestic Phase 3 trial and an NDA filing targeted for H2 2026 marking a pivotal inflection point.

1
INV-002 domestic Phase 3 completed: LPO finalized in April 2026, clinical termination report submitted to MFDS in May 2026, positive interim independent image review data — NDA filing targeted for H2 2026
2
Invinity platform competitive edge: iron-based nano-structure resolves immune cell phagocytosis and ensures 100% metabolic elimination post-examination, offering a clear safety differentiation over gadolinium
3
Strategic partnerships in place: exclusive domestic distribution agreement with Korea's #1 contrast agent distributor Dongguk Life Sciences (Mar 2024) and raw material production contract with LG Chem (Jan 2025)
4
Pre-revenue technology special listing: cumulative negative operating cash flow through Q3 2025 (approx. -4.8 bn won), with ~18.85 bn won in IPO proceeds as the primary funding source for R&D and operations
5
Structural de-gadolinium tailwind: ISMRM environmental contamination advisory, China's rare-earth export controls on gadolinium, and tightening global regulations collectively underpin structural demand for iron-based alternatives

Business structure

Inventera was founded in November 2018 as a nano-medicine R&D company, led by CEO Shin Tae-hyeon and headquartered in Seoul, and went public on KOSDAQ via the technology special-listing pathway.

Its core technology is the proprietary nano-structure platform 'Invinity,' which stabilizes nano-particle surfaces to overcome immune cell phagocytosis—a long-standing limitation of nano-medicines—while ensuring that the iron (Fe) payload undergoes complete metabolic elimination from the body post-examination with no residual accumulation.

The pipeline is led by INV-002 (musculoskeletal MR arthrography-specific contrast agent), followed by lymphovascular agent INV-001 (domestic Phase 2a ongoing), pancreaticobiliary agent INV-003, and cerebrovascular ultra-high-resolution agent INV-00X at the preclinical stage.

The monetization model—designated 'FIDDO (Fully Integrated Drug Development Organization)'—combines direct product sales with global technology licensing in a dual-track approach.

On the commercial side, Inventera signed an exclusive domestic distribution agreement with Dongguk Life Sciences, the leading Korean contrast agent distributor, in March 2024, with approximately 45% of the partner's product sales to be recognized as Inventera's revenue, constituting a highly favorable revenue structure.

In January 2025, a raw material pharmaceutical production contract was signed with LG Chem, solidifying the integrated manufacturing infrastructure from API to finished product.

The company has received government recognition through programs such as TIPS (Ministry of SMEs and Startups) and the Ministry of Health & Welfare's Future Medical Industry One-Stop program, as well as Series C venture financing.

Over the medium to long term, the company is pursuing parallel research into applying the Invinity platform to antibody-drug conjugates (ADC) and theranostics (combined diagnostic and therapeutic modalities).

The global MRI contrast agent market is dominated by GE Healthcare, Bayer, Bracco, and Guerbet with over 90% combined share, making Inventera's differentiation—targeting first-in-class niches in disease-specific indications that incumbents have not addressed—the central competitive rationale.

Recent trends

Inventera made its KOSDAQ debut on April 2, 2026, drawing intense market attention with the share price surging to an intraday high of 60,200 won on its first trading day—more than tripling the IPO price of 16,600 won.

Institutional bookbuilding achieved a competition ratio of 1,328.82:1, while general public subscription recorded 1,913.44:1 with total deposits of approximately 4.69 trillion won, placing the IPO price at the top of the indicative range of 12,100–16,600 won.

The approximately 18.85 billion won raised through 100% new-share issuance is earmarked for INV-002 clinical expenses and operating costs.

However, the share price has declined persistently since listing; as of June 5, 2026, the stock trades at 12,850 won—approximately 22.6% below the IPO price and roughly 78.7% below the 52-week high of 60,200 won.

Financially, the company remains pre-revenue as a pure-play clinical-stage biotech, with operating cash outflows widening from approximately -2.5 billion won in 2022 to a cumulative -4.8 billion won through Q3 2025.

EPS is negative (approximately -1,210 won per available market data), rendering the P/E ratio incalculable; the P/B ratio stands at roughly 3x.

On the clinical front, the company completed the last patient observation (LPO) for INV-002's domestic Phase 3 trial in April 2026, submitted the clinical termination report to the MFDS in May 2026, and secured positive interim data from an independent central image review conducted by three external radiologists—materially advancing preparations for an NDA filing in H2 2026.

Early post-IPO selling by financial investors including Mediatox Venture Investment contributed to initial overhang pressure, and staged lock-up expiries continue to weigh on the supply-demand balance.

Outlook

The most critical near-term event for Inventera is the INV-002 NDA filing in H2 2026, with the company accelerating clinical study report (CSR) preparation through its CRO.

If approved, the exclusive domestic distribution agreement with Dongguk Life Sciences could enable commercialization as early as 2027; the company's internal projections call for 2027 estimated revenue of 4.2 billion won (operating loss of 9.7 billion won) and an inflection to profitability in 2028 at estimated revenue of 25.2 billion won and operating profit of 7.2 billion won.

In the U.S., the FDA-approved IND for INV-002's Phase 2b trial (granted November 2024) positions the company to initiate American clinical operations, a milestone that could serve as a significant re-rating catalyst if confirmed this year.

INV-001 (lymphovascular MRI contrast agent), currently in Phase 2a domestically, targets a white-space market with no globally approved contrast agent, representing a potential additional value creation layer beyond INV-002.

Structurally, the global push toward post-gadolinium MRI solutions—driven by ISMRM environmental contamination advisories, China's rare-earth export controls covering gadolinium, and tightening regulatory guidelines globally—underpins long-term demand for iron-based alternatives.

The domestic contrast agent market grew from 335 billion to 506 billion won between 2015 and 2024, while the global MRI contrast agent market is projected to expand from approximately $5.29 billion in 2023 to $7.52 billion by 2032.

However, persistent pre-revenue cash burn, clinical-stage uncertainty, and the entrenched market position of gadolinium-based agents remain the key variables that could delay the path to earnings realization.

Bull factors

INV-002 Phase 3 Complete and NDA Filing Imminent

INV-002 completed its last patient observation (LPO) in April 2026—just seven months after the first patient in (FPI) in September 2025—and the clinical termination report was submitted to the MFDS in early May 2026, reflecting an accelerated development timeline.

The independent central image review, conducted by a panel of three external radiologists not affiliated with the trial across eight major tertiary hospitals, yielded positive interim findings that enhance scientific credibility.

With the NDA filing targeted for H2 2026 and an exclusive domestic distribution contract in place with Dongguk Life Sciences, the path to first commercial revenues in 2027 is becoming increasingly concrete, potentially serving as a trigger for valuation re-rating.

First-in-Class Positioning with Monopoly Market Upside

All pipeline candidates under development at Inventera are first-in-class drugs targeting indications with no currently approved contrast agents, meaning successful commercialization would confer near-monopoly market positioning ahead of any new entrants.

INV-001, targeting magnetic resonance lymphangiography (MRL), faces a market with no globally approved contrast agent, implying substantially unconstrained addressable market access if licensed.

The fact that the MRI contrast agent space has seen virtually no new molecular entity approvals in over 30 years underscores the structural innovation vacuum that Inventera is positioned to fill, beyond merely incremental product improvement.

Gadolinium Supply Chain Crisis as a Structural Demand Catalyst

Structural headwinds against gadolinium are intensifying: ISMRM formally designated gadolinium as a persistent environmental pollutant, global regulators have tightened gadolinium deposition disease (GDD) monitoring guidelines, and academic research published in 2025 has linked gadolinium accumulation to Parkinson's disease risk.

China controls over 90% of global gadolinium production and refining, and recent rare-earth export controls have introduced material supply chain uncertainty for all four incumbent manufacturers that collectively hold 90%+ of the MRI contrast agent market.

As the clinical-stage developer with the most advanced non-gadolinium iron-based contrast agent, Inventera is distinctly positioned to benefit should the de-gadolinium shift accelerate.

Bear factors

Zero Revenue and Widening Cash Burn

Inventera is a pure-play clinical-stage company with no revenues, and operating cash outflows have widened from approximately -2.5 billion won in 2022 to a cumulative -4.8 billion won through Q3 2025.

While the IPO raised approximately 18.85 billion won, these proceeds are projected to be consumed by R&D and operating expenses through 2028, leaving open the possibility of additional capital raises if the commercialization timeline slips.

Any delay in INV-002's regulatory approval or unexpected clinical setback would intensify working capital pressure and could necessitate dilutive financing, representing a meaningful financial risk for a pre-revenue entity.

Persistent Overhang and Below-IPO Share Price

Approximately 29.87% of total listed shares (about 2.35 million shares) became immediately tradeable upon listing, and financial investors including Mediatox Venture Investment executed partial sell-downs on the first trading day, exerting immediate supply pressure.

As of June 5, 2026, the stock at 12,850 won has fallen approximately 22.6% below the IPO price of 16,600 won, placing a majority of general public subscribers in a loss position roughly two months post-IPO.

With staged lock-up expiries still forthcoming, incremental overhang pressure is likely to persist in the medium term until operating revenues materialize.

Valuation Controversy and Binary Clinical Risk

The IPO price was derived by applying peer-group P/E multiples from earnings-generating companies (Dongguk Life Sciences and Duochem Bio) to Inventera's own 2029 estimated net profit of 18.3 billion won—a methodology that attracted widespread criticism before listing for assigning profitable-company multiples to a pre-revenue entity.

Should INV-002 fail to clear regulatory review or underperform commercial penetration projections, the entire 2027–2028 earnings trajectory would be called into question, triggering substantial downward pressure.

Although the approximately 78.7% correction from the 52-week high partially reflects deflation of early excess enthusiasm, meaningful uncertainty in fair-value estimation persists until operating revenues materialize.

Risk factors

Clinical & Regulatory Risk

The final INV-002 CSR data may not meet MFDS approval criteria, or the regulator may request supplemental data during review, potentially causing material delays to the commercialization timeline. The U.S.

Phase 2b trial (FDA IND approved) has yet to commence, and any protocol changes or unexpected safety signals would set back the global expansion strategy.

Contrast agents face rigorous regulatory expectations across imaging quality, safety, and patient convenience, making approval-delay risk a material concern comparable to that of therapeutic drug developers.

Competitive & Market Penetration Risk

GE Healthcare, the world's leading contrast agent manufacturer, is advancing a manganese-based candidate 'Mn-PyC3A' through Phase 2 clinical development, backed by a distribution network and brand recognition vastly superior to Inventera's.

Gadolinium-based agents have been the clinical standard for over 30 years, and institutional inertia in radiology settings could mean slower-than-expected market penetration for a new entrant.

Domestic health insurance reimbursement negotiations and formulary listing decisions are additional variables that could significantly constrain achievable revenue volumes.

Financial & Dilution Risk

With no current revenues, the company must sustain operations on IPO proceeds alone through the projected 2028 breakeven; any clinical cost overruns or commercialization delays could necessitate additional capital raises through rights offerings or private placements.

As a technology special-listing entity, the underwriter's six-month put-back option could create indirect financial obligations given the share price is already trading below the IPO price.

Should the gap between cash burn velocity and commercialization timeline fail to narrow, dilution risk and shareholder value erosion concerns are likely to remain elevated.

Overall view

Inventera's long-term investment thesis retains structural validity: the company pursues a first-in-class iron-based nano contrast agent in an environment where gadolinium toxicity concerns, environmental risks, and China-driven supply chain fragility are intensifying.

The rapid completion of INV-002's domestic Phase 3 trial across eight major tertiary hospitals, combined with positive interim independent image review data, represents a meaningful advance in the path toward commercial viability.

The key share price catalysts to monitor are the progression of the MFDS NDA review following a targeted H2 2026 filing, the commencement of the U.S. FDA Phase 2b trial, and the potential for global technology licensing agreements.

However, with the share price currently trading below the IPO price and the company remaining pre-revenue, overhang pressure and valuation debate are likely to persist until operating revenues materialize.

The 2028 breakeven scenario is contingent on a sequential chain of milestones—INV-002 regulatory approval, commercial launch, and distribution performance under the Dongguk Life Sciences agreement—any slippage in which could undermine the entire earnings trajectory.

Observers are advised to anchor expectations to verifiable milestones rather than terminal-year projections, while treating clinical failure and dilutive capital raises as the primary tail risks to monitor.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 12 more articles and sources

Report written 2026-06-05 · Data as of 2026-06-05

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.